文献速递脑血管病外科神经重症

RECOVER研究:克拉生坦与法舒地尔治疗动脉瘤性蛛网膜下腔出血患者的多中心回顾性队列疗效与安全性比较

RECOVER study: a multicenter retrospective cohort study and comparison of the efficacy and safety of clazosentan and fasudil in patients with aneurysmal subarachnoid hemorrhage.
PubMed 文献 · J Neurosurg · 2025-05-16

该多中心回顾性队列研究纳入466例动脉瘤性蛛网膜下腔出血患者,比较克拉生坦与法舒地尔围手术期管理的疗效与安全性。克拉生坦组造影性脑血管痉挛和痉挛相关延迟性脑缺血发生率均显著低于法舒地尔组,出院时mRS 0-2分比例显著更高。两组肺部并发症和脑水肿发生率无显著差异。

要点

  • 克拉生坦组造影性脑血管痉挛发生率15.4%,显著低于法舒地尔组的33.7%(p<0.001)。
  • 克拉生坦组痉挛相关延迟性脑缺血发生率4.4%,显著低于法舒地尔组的10.2%(p=0.007)。
  • 出院时mRS 0-2分比例克拉生坦组62.2%,显著高于法舒地尔组的50.5%(p=0.005)。

核心结论

  • 克拉生坦在预防脑血管痉挛和改善动脉瘤性蛛网膜下腔出血患者总体结局方面优于法舒地尔。
  • 尽管初期担忧液体潴留,适当的围手术期管理减轻了这些风险,使克拉生坦成为不同患者群体中的更优治疗选择。

研究设计与样本

  • 多中心回顾性观察性队列研究,纳入466例动脉瘤性蛛网膜下腔出血患者。
  • 按围手术期管理分为克拉生坦组或法舒地尔组,采用逆概率治疗加权调整选择偏倚。

主要发现

  • 克拉生坦组造影性脑血管痉挛发生率15.4%,法舒地尔组33.7%(p<0.001)。
  • 克拉生坦组痉挛相关延迟性脑缺血发生率4.4%,法舒地尔组10.2%(p=0.007)。
  • 出院时mRS 0-2分比例克拉生坦组62.2%,法舒地尔组50.5%(p=0.005)。
  • 两组肺部并发症和脑水肿发生率无显著差异。
  • 克拉生坦可能对重症病例或≥75岁老年患者也有效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Delayed cerebral ischemia (DCI) is a crucial determinant of the prognosis of patients with aneurysmal subarachnoid hemorrhage (aSAH). In Japan, fasudil has traditionally been used to prevent cerebral vasospasm after aSAH. The effectiveness of clazosentan, a selective endothelin receptor A antagonist, in preventing cerebral vasospasm, a significant contributor to DCI, was recently demonstrated. This study aimed to compare the efficacy and safety of perioperative management using clazosentan- and fasudil-based therapies. METHODS: This multicenter, retrospective observational cohort study included 466 patients with aSAH. Patients were categorized into two groups based on the perioperative management administered: clazosentan or fasudil. Data on patient characteristics, treatment outcomes (assessed using the modified Rankin Scale [mRS] at discharge), and complications (including angiographic cerebral vasospasm, vasospasm-related DCI, pulmonary complications, hypotension, brain edema, and de novo intracerebral hemorrhage) were collected. Statistical analyses were conducted using inverse probability of treatment weighting to adjust for selection bias. RESULTS: Clazosentan was significantly more effective than fasudil in preventing angiographic cerebral vasospasm (33.7% of fasudil-treated patients had vasospasm vs 15.4% of clazosentan-treated patients, p < 0.001) and vasospasm-related DCI (10.2% fasudil vs 4.4% clazosentan, p = 0.007). This improved effectiveness resulted in significantly better outcomes at discharge (50.5% of fasudil-treated patients had an mRS score of 0-2 vs 62.2% of clazosentan-treated patients, p = 0.005). Although clazosentan has been reportedly associated with fluid retention complications, no significant differences in the incidence rates of pulmonary complications or brain edema were found between the groups in this study, likely because of improved fluid management protocols. Clazosentan may also be effective in severe cases or for use in elderly patients aged ≥ 75 years. CONCLUSIONS: Clazosentan outperformed fasudil in preventing cerebral vasospasm and improving overall outcomes in patients with aSAH. Despite initial concerns regarding fluid retention, appropriate perioperative management mitigated these risks, making clazosentan a superior treatment option across different patient groups.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Muraoka S, Izumi T, Nishida K, et al. RECOVER study: a multicenter retrospective cohort study and comparison of the efficacy and safety of clazosentan and fasudil in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg. 2025. PMID: 40378483. doi:10.3171/2025.1.JNS242509

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。